Results 11 to 20 of about 14,491 (226)

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report

Frontiers in Pharmacology
Anaplastic lymphoma kinase (ALK) inhibitor alectinib has demonstrated significant potential in treating non-small cell lung cancer (NSCLC); however, its adverse effects remain a notable challenge for healthcare professionals.
Yun Li, Ping Yu, Ran Wang
doaj   +2 more sources

Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements

Therapeutic Advances in Medical Oncology
Background and objectives: This study aimed to compare the efficacy of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and brigatinib in the treatment of advanced non-small-cell lung cancer (NSCLC) with ...
Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, Ah Young Shin, Sung Kyoung Kim, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim, Jeong Uk Lim, Chang Dong Yeo   +9 more
doaj   +2 more sources

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study

JTO Clinical and Research Reports
Introduction: Previous results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced ALK-positive NSCLC, consistent
Caicun Zhou, MD, PhD, You Lu, MD, Sang-We Kim, MD, PhD, Thanyanan Reungwetwattana, MD, Jianying Zhou, MD, Yiping Zhang, MD, Jianxing He, MD, PhD, Jin-Ji Yang, MD, Ying Cheng, MD, Se-Hoon Lee, MD, PhD, Jianhua Chang, MD, Jian Fang, MD, Zhe Liu, PhD, Lilian Bu, MSc, Li Qian, MD, Tingting Xu, MD, Venice Archer, MB ChB, MSc, Magalie Hilton, MSc, Mingzhu Zhou, MSc, Li Zhang, MD   +19 more
doaj   +2 more sources

A Case of Lung Adenocarcinoma With Concurrent EGFR Mutation and ALK Fusion Combined With Literature Review. [PDF]

Clin Case Rep
ABSTRACT This case underscores the critical importance of retesting for resistant mechanisms, such as EML4‐ALK fusion, in patients with EGFR‐mutant lung adenocarcinoma who experience rapid progression on EGFR‐tyrosine kinase inhibitor (TKI) therapy. Early identification of such co‐alterations and an immediate switch to alectinib can lead to rapid and ...
Chen Y, Qi F, Zeng Y, Tan J, Hu M, Zhang H, Zhang T.   +6 more
europepmc   +2 more sources

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement

Frontiers in Oncology
BackgroundAlectinib has demonstrated promising disease-free survival (DFS) benefit for early-stage non-small cell lung cancer (NSCLC) patients with ALK rearrangement positive in phase 3 ALINA trial.
Zeng-Hao Chang, Teng-Fei Zhu, Wei Ou, Hao Jiang, Si-Yu Wang   +4 more
doaj   +2 more sources

Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison. [PDF]

J Comp Eff Res
Aim: Lorlatinib demonstrated superior efficacy over alectinib as a first-line treatment for ALK-positive (ALK+) advanced/metastatic non-small cell lung cancer in a matching-adjusted indirect comparison (MAIC) using 3-year follow-up data from CROWN ...
Bauer T, Abrahami D, Polli A, Chu H, Ramachandran P, Chandler C, Tan M, Truscott J, Mazieres J, Garcia CA.   +9 more
europepmc   +2 more sources

Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling

Clinical and Translational Science, 2023
Alectinib, approved as 150 mg capsules for the treatment of adults with advanced ALK‐positive non‐small cell lung cancer, is being assessed in children with ALK‐positive solid and central nervous system tumors.
Stephanie N. Liu, Priya Agarwal, Katja Heinig, Asim Datye, Carolina Sturm‐Pellanda, Andrea Crugnola, Marc Arca, Dale Miles   +7 more
doaj   +1 more source

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports

Frontiers in Oncology, 2023
ObjectiveDespite the promising efficacy and tolerability of alectinib in treating advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), the role of alectinib in neoadjuvant setting remains understudied in ALK-rearranged ...
Liang Shi, Shuhong Gao, Li Tong, Qiyi Meng, Shijie Zhou, Daping Yu, Yujie Dong, Zhe Liu   +7 more
doaj   +1 more source

Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC—A Case Report

JTO Clinical and Research Reports, 2023
The emergence of spontaneous nonmalignant chylous effusions during treatment with various tyrosine kinase inhibitors (TKIs) has been previously described; however, there have been no prior reports for alectinib.
Sunanjay Bajaj, MD, Andrew Chow, MD, PhD, Alexander Drilon, MD, Or Kalchiem-Dekel, MD   +3 more
doaj   +1 more source

Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease

BMC Pulmonary Medicine, 2017
Background Alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, is a key drug for ALK rearranged lung adenocarcinoma. Interstitial lung disease (ILD) is an important adverse effect of alectinib, which generally requires termination ...
Tatsuya Nitawaki, Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado   +3 more
doaj   +1 more source